Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

 CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer

Business Wire January 3, 2022

CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

Business Wire December 21, 2021

CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

Business Wire November 30, 2021

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

Business Wire November 12, 2021

CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

Business Wire November 9, 2021

CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C

Business Wire November 2, 2021

CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment

Business Wire October 14, 2021

CytRx to Present at Upcoming Virtual LD Micro Conference

Business Wire October 5, 2021

CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Business Wire September 8, 2021

CytRx Highlights Orphazyme's Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C

Business Wire August 24, 2021

Johnson Fistel, Announces Investigations of NantKwest, Inc., K12 Inc., and CytRx Corporation; Long-Term Investors Encouraged to Contact Firm

PR Newswire October 4, 2017

Institutional Shareholder Services, Inc., Recommends CytRx Corporation Stockholders Vote "FOR" the Proposed Reverse Stock Split

PR Newswire October 4, 2017

Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics

PR Newswire October 3, 2017

CytRx Corporation Provides Business Update and Highlights Future Plans

PR Newswire October 2, 2017

Leading Independent Proxy Advisory Firm Glass Lewis & Co. Recommends CytRx Corp. Stockholders Vote "FOR" the Proposed Reverse Stock Split

PR Newswire September 21, 2017

CytRx Corporation Announces Amendment to Definitive Proxy Statement for Upcoming Special Meeting

PR Newswire September 13, 2017

Recent Developments in the Pharmaceutical Industry

PR Newswire September 5, 2017

CytRx Corporation Files Definitive Proxy Statement for Upcoming Special Meeting

PR Newswire August 30, 2017

CytRx Corporation Announces Receipt of NASDAQ Listing Determination

PR Newswire August 24, 2017

CytRx Corporation Files Preliminary Proxy Statement for Upcoming Special Meeting

PR Newswire August 21, 2017